Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Amortization of Deferred Charges (2020 - 2021)

Historic Amortization of Deferred Charges for Apellis Pharmaceuticals (APLS) over the last 2 years, with Q4 2021 value amounting to $3000.0.

  • Apellis Pharmaceuticals' Amortization of Deferred Charges fell 7692.31% to $3000.0 in Q4 2021 from the same period last year, while for Dec 2021 it was $113000.0, marking a year-over-year decrease of 4909.91%. This contributed to the annual value of $113000.0 for FY2021, which is 4909.91% down from last year.
  • Apellis Pharmaceuticals' Amortization of Deferred Charges amounted to $3000.0 in Q4 2021, which was down 7692.31% from -$8000.0 recorded in Q3 2021.
  • In the past 5 years, Apellis Pharmaceuticals' Amortization of Deferred Charges ranged from a high of $125000.0 in Q3 2020 and a low of -$8000.0 during Q3 2021